April 29, 2020 | Blog
Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?
Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.